New Materials Late Stage Investors & VC Firms
285 firms in this list, with a median first check of $1M. 49 of them lead rounds. Generated from verified public data and updated continuously.
Darwin Venture Management
TaipeiSeed–Late Stage$1M – $76M
Elmirate Capital
DubaiSeed–Late Stage$15M – $150M
Fulcrum Financial Partners
Raleigh-DurhamPre-Seed–Late Stage
3 people
GRIDS Capital
São PauloSeed–Late Stage
3 people
Hony Capital Ltd.
Grand Cay C Ay IslGrowth–Late Stage$6M
6 people
Innovation Engine
TokyoPre-Seed–Late Stage
3 people
IRDI SORIDEC Gestion
ToulouseSeed–Late Stage$216K – $16.2M
ONCAP
TorontoGrowth–Late Stage$20M – $250M
Rivus Capital
MunichSeed–Late Stage$5M – $20M
Mohr Davidow Ventures
San MateoSeed–Late Stage$200K – $4M
5 people
Cathay Health
San FranciscoSeed–Late Stage
1 person
Aurum Ventures MKI
Ramat GanSeed–Late Stage
8 people
Trans-Pacific Technology Fund
TaipeiSeed–Late Stage
8 people
Honda Innovations Silicon Valley
TokyoPre-Seed–Late Stage
2 people
Nexus Capital Management
Los AngelesSeries C–Late Stage
1 person
Kiko Ventures
LondonPre-Seed–Late Stage
1 person
NJF Capital
LondonSeed–Late Stage
1 person
The Wells Investment
SeoulSeed–Late Stage
Bioenterprise Canada
GuelphSeed–Late Stage
1 person
Haibang Capital
HangzhouPre-Seed–Late Stage
1 person
Hokkaido Venture Capital, Inc.
SapporoPre-Seed–Late Stage
1 person
AXIS Participaciones Empresariales
MadridSeed–Late Stage$810K – $43.2M
4 people
Solus Capital
BudapestSeed–Late Stage$32.4K – $4.3M
4 people
Chemelot Ventures
Seed–Late Stage
Related lists
Late Stage Investors & VC Firms (2864)Late Stage Investors & VC Firms in United States (1101)New Materials Investors & VC Firms (1069)New Materials Seed Investors & VC Firms (876)Late Stage Investors & VC Firms in Global (857)Healthtech Late Stage Investors & VC Firms (847)New Materials Series A Investors & VC Firms (822)Enterprise Software Late Stage Investors & VC Firms (801)SaaS Late Stage Investors & VC Firms (784)Fintech Late Stage Investors & VC Firms (656)
Data sourced from public filings and firms' own websites — see our methodology.





